Glioblastoma

PhaseV Unveils Machine Learning-Powered Platform to Improve Oncology Clinical Trials

Retrieved on: 
Thursday, September 12, 2024
Patient, Clinical trial, FDA, HTE, Doctor of Philosophy, ESMO, PD-L1, Glioblastoma, Ipilimumab, Congress, Software, ChromeOS, Patient safety, Nivolumab, Machine learning, Efficacy, Metastasis, Lung cancer, NSCLC, Pharmaceutical industry

BOSTON, Sept. 12, 2024 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today the latest capabilities of its AdaptV platform to increase the efficiency and success rates of oncology clinical trials. AdaptV is an interactive machine learning-based simulation platform that enables drug developers to effectively design adaptive clinical trials through an intuitive and user-friendly interface.

Key Points: 
  • BOSTON, Sept. 12, 2024 /PRNewswire/ -- PhaseV , a pioneer in software and machine learning (ML) for clinical trial optimization, announced today the latest capabilities of its AdaptV platform to increase the efficiency and success rates of oncology clinical trials.
  • AdaptV is an interactive machine learning-based simulation platform that enables drug developers to effectively design adaptive clinical trials through an intuitive and user-friendly interface.
  • Used in Phase I and Phase I/II oncology clinical trials, these studies allow for faster identification of the optimal dose of a new treatment with fewer patients while maintaining patient safety.
  • In addition to adaptive trial designing, PhaseV offers a unique set of Causal-ML models for advanced clinical trial analysis.

BPGbio Presents Phase 2b BPM31510 Glioblastoma Trial-in-Progress Update and Pioneering Comprehensive Quinomics Assessment at the ESMO Congress 2024

Retrieved on: 
Thursday, September 12, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Neurology, Health Technology, Research, Artificial Intelligence, Science, Clinical Trials, Drug development, Stanford University, GBM, Patient, Brain, Clinical trial, Neurosurgery, ESMO, Vitamin K, Congress, Glioblastoma, MD, Medical imaging

BPGbio, Inc ., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis , today announced that researchers will present two posters on the ongoing phase 2 trial ( NCT04752813 ) of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM) at the European Society for Medical Oncology (ESMO) Congress 2024 , taking place September 13-17 in Barcelona.

Key Points: 
  • BPGbio, Inc ., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis , today announced that researchers will present two posters on the ongoing phase 2 trial ( NCT04752813 ) of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM) at the European Society for Medical Oncology (ESMO) Congress 2024 , taking place September 13-17 in Barcelona.
  • Seema Nagpal , MD, Clinical Professor of Neurology at Stanford Medicine and principal investigator of the trial, will be presenting the latest data from the ongoing trial which has enrolled sixteen (16) patients and seven (7) completed the study.
  • Dr. Nagpal and her colleagues at Stanford will also present the cutting-edge quinomics assessment of BPM31510 which shows visualized in vivo effect of the drug on an experimental glioma model and in the brain and provides data validating metabolic activity.
  • “We are excited to present the latest data from the BPM31510 GBM phase 2 trial at the ESMO Congress,” said Dr. Seema Nagpal , Clinical Professor of Neurology at Stanford Medicine and principal investigator of the trial.

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, September 9, 2024
Diabetes, Therapy, Mesothelioma, Poster, Monroe Dunaway Anderson, Glioblastoma, TUSC2, Cancer, Lung cancer, Potential, Research, Patient, Pharmaceutical industry

AUSTIN, Texas, Sept. 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024 in Barcelona, Spain. The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.

Key Points: 
  • The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.
  • Featured Genprex-supported posters to be presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics include:
    Genprex has filed two provisional patent applications based on data from two of the presentations.
  • REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge.
  • REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue.

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Retrieved on: 
Monday, September 9, 2024
Progression-free survival, Research, Inflammation, FDA, Bangladesh Technical Education Board, NU, United, Safety, Glioblastoma, Isocitrate dehydrogenase, Associate, Cancer, Glioma, Virus, IND, Metastasis, Neoplasm, NIH, Survival, Investigational New Drug, Patient, Incidence, Food, IDH, STAT3, Neurosurgery, Radiation, Person, Brain, Factorization of polynomials, Pharmaceutical industry

HOUSTON, Sept. 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the enrollment and treatment of patients in an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma (NU 21C06). The study is being conducted under Northwestern University's Investigative New Drug application (IND) which cross references the Company's own IND, which received clearance from the U.S. Food and Drug Administration (FDA) in April 2022. This trial is funded by the National Institutes of Health (NIH) and BrainUp®, a non-profit organization dedicated to bringing awareness to brain cancer.

Key Points: 
  • This trial is funded by the National Institutes of Health (NIH) and BrainUp®, a non-profit organization dedicated to bringing awareness to brain cancer.
  • The NU 21C06 trial is a Phase 2, open-label, multi-arm trial of radiation therapy in combination with WP1066 in newly diagnosed IDH (isocitrate dehydrogenase) wild-type, MGMT-unmethylated glioblastoma patients.
  • If treatment is well tolerated in these subjects, we will continue enrollment for the balance of the trial."
  • For more information about the NU 21C06 Phase 2 study, visit clinicaltrials.gov and reference identifier NCT05879250 .

EQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Retrieved on: 
Monday, September 9, 2024
CVAC, CureVac, Congress, Vaccine, ESMO, Safety, Cancer, Data monitoring committee, Glioblastoma, Astrocytoma, Oncology, Messenger, Patient, Epitope, Brain, Part

TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first clinical data from CureVac’s ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024).

Key Points: 
  • TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first clinical data from CureVac’s ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024).
  • Clinical data will be presented as an oral presentation on Friday, September 13, along with a poster presentation of preclinical data supporting the program’s development.
  • The Phase 1 study is evaluating the safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-promoter unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma.
  • CVGBM features a single unmodified mRNA encoding eight epitopes derived from known tumor-associated antigens, with demonstrated immunogenicity in glioblastoma.

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

Retrieved on: 
Friday, September 6, 2024
Research, Philanthropy, Biotechnology, General Health, Pharmaceutical, Health, Foundation, Other Philanthropy, Science, Oncology, Creativity, Love, Bristol Myers Squibb, BMS, Glioblastoma, Cancer, BMY, Disease, Patient, Multimedia, Senior, Memory, Motivation, USD, Friends, Hematology, Jim Valvano, Pharmaceutical industry

With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will relay Coast 2 Coast 4 Cancer (C2C4C) this year and cycle from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research .

Key Points: 
  • With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will relay Coast 2 Coast 4 Cancer (C2C4C) this year and cycle from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research .
  • Since the ride’s inception in 2014, Bristol Myers Squibb employees – many of whom have been personally impacted by cancer – have come together to fundraise, resulting in more than $12.7 million in donations for cancer research in North America.
  • The money raised this year by the Coast 2 Coast 4 Cancer riders will be matched dollar-for-dollar by Bristol Myers Squibb, up to $500,000.
  • C2C4C has become a purposeful tradition at Bristol Myers Squibb, with more than $16 million USD donated globally for cancer research to date.

SageMedic Corp. Announces Formation of its Scientific and Medical Advisory Board to Significantly Advance Precision Medicine for Cancer Patients

Retrieved on: 
Thursday, September 5, 2024
Neurology, Surgical oncology, MD, Oncology, MGH, Ovarian cancer, Translational research, Glioblastoma, SAB, Doctor of Philosophy, MBA, Associate, Wake Forest University, Human, PALO, American Cancer Society, CNS, Hospital, Therapy, Cancer, Patient, Stanford University, Science, Malignancy, Harvard Medical School, Silicon, Medicine, SAGE, MD Anderson Cancer Center, Massachusetts General Hospital, Central nervous system

Comprised of distinguished authorities in cancer research and medical and surgical oncology, the board reflects SageMedic's commitment to significantly enhance the precision of cancer diagnostics by enabling oncologists to more effectively tailor therapies to individual patient needs.

Key Points: 
  • Comprised of distinguished authorities in cancer research and medical and surgical oncology, the board reflects SageMedic's commitment to significantly enhance the precision of cancer diagnostics by enabling oncologists to more effectively tailor therapies to individual patient needs.
  • William Cance, MD, former Chief Medical and Scientific Officer at the American Cancer Society, leads the Scientific and Medical Advisory Board.
  • According to Dr. Cance, "Cancer poses profound challenges, with many advancements offering only marginal benefits to patients.
  • Their unparalleled expertise will continue to push the boundaries of what is possible in precision medicine to truly personalize therapies for cancer patients."

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Retrieved on: 
Wednesday, September 4, 2024
Methylation, Orphan, TCG, Diagnosis, RT, Glioblastoma, University, CPA, Internet, Survival, Cancer, Brain, IDH, Radiation, PC, Clinical trial, Disease, Annual report, API, LLP, Quality of life, FDA, Marketing, Patient, Pharmaceutical industry

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024.

Key Points: 
  • GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024.
  • Shuttle Pharma expects the Phase 2 clinical trial will be carried out at six site locations, with two sites now ready to start treating patients and all sites anticipated to be treating patients in the coming months.
  • Shuttle Pharma has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease.
  • Following these filings, Shuttle Pharma has now regained compliance with Listing Rule 5250(c).

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Retrieved on: 
Wednesday, September 4, 2024
GBM, Progression-free survival, Glioblastoma, MDS, ALL, Cancer, Acute myeloid leukemia, Partnership, Workforce, Clinical trial, AML, Leukemia, FDA, Patient, UAB, TP53, Pharmaceutical industry

Company to preserve its cash resources with anticipated clinical cost savings and a workforce reduction of 49%, which is expected to be completed in 3Q24.

Key Points: 
  • Company to preserve its cash resources with anticipated clinical cost savings and a workforce reduction of 49%, which is expected to be completed in 3Q24.
  • The Company will focus on generating robust clinical data from INB-100, the ongoing investigator-sponsored Phase 1 clinical trial of acute myeloid leukemia (AML), to further de-risk the registrational pathway and affirm the 100% one-year progression-free survival observed to date in this patient population.
  • The Company will suspend its glioblastoma (GBM) development program while continuing to monitor patients in the Phase 1 INB-200 clinical trial and those enrolled in the Phase 2 INB-400 clinical trial.
  • IN8bio expects to incur one-time costs of approximately $0.3 million in connection with the workforce reduction, of which nearly all are cash expenditures related to severance.

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

Retrieved on: 
Tuesday, September 3, 2024
Safety, GBM, Progression-free survival, Diagnosis, Standard of care, Glioblastoma, 18F-FET, Survival, Kidney, PET, TLX, Toxicity, Radiation, Paper, Disease, Metabolism, LAT1, Patient, EBRT, OS, ASX, Medical imaging

TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in GBM.

Key Points: 
  • TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in GBM.
  • Key findings of the IPAX-1 study, outlined in the paper, include:
    All dosing regimens were well tolerated.
  • The results from this Phase I study demonstrate the favorable safety and tolerability profile and preliminary efficacy of TLX101 in combination with second-line EBRT, in patients with recurrent glioblastoma.
  • Data from IPAX-1, together with these studies, will inform the design of Telix’s future registration-enabling trial for TLX101.